Sagimet Biosciences Inc. Diluted Shares Outstanding (Weighted Average)
Sagimet Biosciences Inc. (SGMT) reported Diluted Shares Outstanding (Weighted Average) of 53.11 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-11
- Sagimet Biosciences Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 53.11M shares, a 64.98% increase year-over-year.
- Sagimet Biosciences Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 32.56M shares, a 1.13% increase year-over-year.
- Sagimet Biosciences Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 32.52M shares, a 0.71% increase year-over-year.
- Sagimet Biosciences Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 32.46M shares, a 1.00% increase year-over-year.
- Sagimet Biosciences Inc. weighted average number of shares outstanding, diluted for fiscal 2025 was 32.35M shares, a 3.17% increase from fiscal 2024.
- Sagimet Biosciences Inc. weighted average number of shares outstanding, diluted for fiscal 2024 was 31.35M shares, a 199.71% increase from fiscal 2023.
- Sagimet Biosciences Inc. weighted average number of shares outstanding, diluted for fiscal 2023 was 10.46M shares, a 5565.90% increase from fiscal 2022.
- Sagimet Biosciences Inc. weighted average number of shares outstanding, diluted for fiscal 2022 was 184.62K shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 53.11M shares 10-Q · filed 2026-08-11 | 42.89M shares 10-Q · filed 2026-08-11 | 39.40M shares derived: average of 3 quarters · filed 2026-08-11 | 37.67M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 32.56M shares 10-Q · filed 2026-05-12 | 32.54M shares derived: average of 2 quarters · filed 2026-05-12 | 32.52M shares derived: average of 3 quarters · filed 2026-05-12 | 32.44M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | 32.52M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | 32.49M shares derived: average of 2 quarters · filed 2026-03-11 | 32.39M shares derived: average of 3 quarters · filed 2026-08-11 | 32.35M shares 10-K · filed 2026-03-11 |
| 2025-09-30 | 32.46M shares 10-Q · filed 2025-11-13 | 32.33M shares derived: average of 2 quarters · filed 2026-08-11 | 32.29M shares 10-Q · filed 2025-11-13 | 32.29M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | 32.20M shares 10-Q · filed 2026-08-11 | 32.20M shares 10-Q · filed 2026-08-11 | 32.23M shares derived: average of 3 quarters · filed 2026-08-11 | 32.21M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | 32.20M shares 10-Q · filed 2026-05-12 | 32.24M shares derived: average of 2 quarters · filed 2026-05-12 | 32.21M shares derived: average of 3 quarters · filed 2026-05-12 | 32.14M shares derived: average of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | 32.29M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | 32.22M shares derived: average of 2 quarters · filed 2026-03-11 | 32.12M shares derived: average of 3 quarters · filed 2026-03-11 | 31.35M shares 10-K · filed 2026-03-11 |
| 2024-09-30 | 32.14M shares 10-Q · filed 2025-11-13 | 32.03M shares derived: average of 2 quarters · filed 2025-11-13 | 31.04M shares 10-Q · filed 2025-11-13 | 29.14M shares derived: average of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | 31.91M shares 10-Q · filed 2025-08-13 | 30.48M shares 10-Q · filed 2025-08-13 | 28.13M shares derived: average of 3 quarters · filed 2025-08-13 | 25.65M shares derived: average of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | 29.04M shares 10-Q · filed 2025-05-08 | 26.24M shares derived: average of 2 quarters · filed 2025-05-08 | 23.56M shares derived: average of 3 quarters · filed 2025-05-08 | 17.72M shares derived: average of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | 23.45M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | 20.82M shares derived: average of 2 quarters · filed 2025-03-12 | 13.94M shares derived: average of 3 quarters · filed 2025-03-12 | 10.46M shares 10-K · filed 2025-03-12 |
| 2023-09-30 | 18.19M shares 10-Q · filed 2024-11-14 | 9.19M shares derived: average of 2 quarters · filed 2024-11-14 | 6.13M shares 10-Q · filed 2024-11-14 | 4.69M shares derived: average of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | 189.52K shares 10-Q · filed 2024-08-14 | 187.31K shares 10-Q · filed 2024-08-14 | 186.29K shares derived: average of 3 quarters · filed 2024-08-14 | 185.99K shares derived: average of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | 185.14K shares 10-Q · filed 2024-05-15 | 184.67K shares derived: average of 2 quarters · filed 2024-05-15 | 184.81K shares derived: average of 3 quarters · filed 2024-05-15 | 184.88K shares derived: average of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | 184.21K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | 184.65K shares derived: average of 2 quarters · filed 2024-03-25 | 184.79K shares derived: average of 3 quarters · filed 2024-03-25 | 184.62K shares 10-K · filed 2024-03-25 |
| 2022-09-30 | 185.08K shares 10-Q · filed 2023-11-13 | 185.08K shares derived: average of 2 quarters · filed 2023-11-13 | 184.76K shares 10-Q · filed 2023-11-13 | |
| 2022-06-30 | 185.08K shares 10-Q · filed 2023-08-21 | 184.59K shares 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |